We examined the protective effects of Mycobacterium bovis bacillus Calmette-Guerin (BCG) administration on Leishmania major infections of BALB/c and P/J mice. There were two treatment protocols. In the first, the footpads of naive animals were inoculated with mixtures of L. major and BCG (viable or heat killed) or the soluble mycobacterial antigen, purified protein derivative. Viable BCG, but not heat-killed BCG or purified protein derivative, inoculated with L. major amastigotes into the footpads of naive BALB/c or PlJ mice protected these animals from the metastatic spread of parasites to the viscera and from ensuing lethal systemic infection. This treatment also induced cures of the cutaneous lesions of P/J mice but not of BALB/c mice. In the second protocol, we induced an immune response to BCG before inoculation of L. major. BCG given intraperitoneally 10 days before infection of footpads with leishmania offered protection against the metastatic spread of amastigotes in both P/J and BALB/c mice, regardless of intralesional treatment, and modulated the severity of cutaneous infection by 30 to 50%. Inoculation of a mixture of viable BCG and L. major amastigotes into BCG-immune mice completely protected both BALB/c and P/J strains from cutaneous disease; we recovered no parasites from the inoculated footpads of these animals. Furthermore, each of the nonspecifically protected mice of both the BALB/c and P/J strains developed immunity to rechallenge with viable L. major.
amastigotes into footpads induces a cutaneous lesion, early metastatic spread of parasites to the viscera, and death of the animal, usually by 12 weeks (2, 12) . P/J mice are qualitatively similar to BALB/c mice in susceptibility to L. major. Inoculation of amastigotes into the footpads of P/J mice also leads to cutaneous infection and systemic disease. Parasites metastasize to the spleen and liver and set up foci of infection that ultimately result in death of the animal. The difference in susceptibility between P/J and BALB/c mice is quantitative; 100-fold more parasites are required to induce lethal disease in P/J mice by 12 weeks (7) .
Resolution of infection by the obligate intracellular parasite L. major in all mouse strains is dependent upon the development of an effective cell-mediated immunity that leads to intracellular destruction of amastigotes (25) . Such protective cell-mediated immune events are presumed to include the generation of soluble products by specifically sensitized lymphocytes (lymphokines [LK] ) and consequential activation of macrophages for intracellular killing activities. Susceptibility of BALB/c and P/J mice to L. major infection is the result of defective immune responses by these animals. Macrophages from both BAL13/c and P/J mice fail to control intracellular replication of L. major at the site of the cutaneous lesion and within infected viscera. The underlying basis for this defective cellular response is not clear, but several lymphocyte and macrophage defects have been demonstrated in both leishmania-susceptible mouse strains that may contribute to exacerbated disease. (i) BALB/c and P/J mice have defective macrophage responses to LK for induction of potent killing mechanisms in vitro (3, 19, 20) . (ii) Adherent cells, phenotypically identified as * Corresponding author.
macrophages, that suppress normal lymphocyte function are observed in spleen cell suspensions from L. major-infected BALB/c mice (28) . (iii) BALB/c and P/J lymphocytes have reduced capacity to produce macrophage-activating LK in response to antigens or mitogens in vitro (4, 16, 18, 27) . (iv) BALB/c mice develop a unique population of suppressor T lymphocytes during leishmanial disease (13, 30) .
Although it is very difficult to distinguish causative factors from epiphenomena in lengthy chronic diseases such as the leishmaniases, two immunodeficiencies discussed above are shared by both susceptible P/J and BALB/c mice: defective LK production in response to antigens or mitogens for induction of macrophage activation and defective macrophage response to LK for intracellular parasite killing. Intuitively, both of these efferent activities of the immune response must be operative for resolution of leishmanial disease. How might one induce these critical activities during an infectious process that characteristically results in a suppressive response in the host? One way to achieve functional augmentation of the immune system is by the use of immunostimulatory agents, such as Mycobacterium bovis BCG and Propionibacterium acnes. The literature is replete with documentation of the immunoenhancing effects of BCG. There are two of particular relevance to this study. (i) BCG infections have systemic effects, as evidenced by an increase in the levels of interferon in serum, a potent LK for activation of macrophages to kill intracellular L. major (33) .
(ii) BCG inoculation leads to local inflammation, followed by development of an immune response with LK production and induced macrophage activation for killing of intracellular and extracellular targets (22, 24, 26) .
These unique and potent immunostimulatory properties of BCG have been practically applied in protection studies with a number of infectious and neoplastic agents (8, 23, 34) , including several species of leishmania. Treatment of leish-maniasis with BCG has been only variably successful. Intraperitoneal (i.p.) or subcutaneous inoculation of C3H mice with BCG did not alter lesion size in Leishmania mexicanainfected animals (9) . Intravenous pretreatment of BALB/c mice with BCG was protective against systemic L. major disease but did little to protect these animals from cutaneous infection (32) . The cellular functions defective in L. majorsusceptible P/J and BALB/c mice, LK production and macrophage activation, are precisely those augmented during BCG infection. In this study we identified BCG treatment protocols that protected mice from both cutaneous and systemic L. major infections. In addition, we demonstrated an adjuvant effect of BCG: animals protected against primary infection were resistant to reinfection with L. major inoculated at sites remote from the original infectious area.
( MATERIALS AND METHODS Animals. Six-to eight-week-old male P/J and BALB/c mice were purchased from Jackson Laboratory, Bar Harbor, Maine. The mice were housed in a barrier environment throughout these studies and were tested periodically for inapparent infection with common murine viruses. The animals remained serologically negative for these agents.
Parasites. L. major NIH 173 amastigotes were propagated in the footpads of 6-to 8-week-old male BALB/c mice. Parasites were harvested from footpads infected for 3 to 4 weeks, according to the method previously described (21 Figure 1 shows the development of cutaneous disease in BALB/c and P/J mice over 12 weeks. The combination of L. major amastigotes and live BCG resulted in decreased lesion size in BALB/c mice. No BCG treatment, however, could completely protect these animals from cutaneous disease (Fig. IA) . Microscopic examination of infected footpad tissue showed that lesions of all sizes were characterized by a preponderance of macrophages that were heavily infected with L. major. Concurrent BCG infections in L. major-inoculated P/J mice, on the other hand, completely protected these animals from cutaneous leishmaniasis (Fig. 1B) . Micros-copic analysis of these inoculated footpad tissues, in contrast to those of BALB/c mice, showed no evidence of L. major. There were, however, numerous acid-fast bacilli, and the cells were characteristic of an inflammatory infiltrate (polymorphonuclear leukocytes, macrophages, and few lymphocytes). Viability of BCG was essential for clearance of the leishmania inoculum, since protection was not observed when P/J mice were treated with heat-killed BCG.
(ii) Effects on systemic disease. Four to eight weeks after cutaneous disease is established in susceptible BALB/c and P/J mice, parasites metastasize to the liver and spleen (7) . The resulting systemic infection progresses unchecked in these animals and eventually leads to death of the infected mice in 10 to 18 weeks. We analyzed the extent of systemic disease by quantitation of liver metastases at 12 weeks in BCG-treated and control mice (Fig. 2) . The incidence of liver metastases in BCG-treated mice of both strains was markedly different from that of untreated BALB/c and P/J mice. Viable BCG given concurrently with L. major protected P/J mice from lethal systemic disease. Even induced an immune response to BCG before inoculation of L. major into the footpads of BALB/c and P/J mice. Mice inoculated with 107 CFU of BCG i.p. were tested 8 to 10 days later for DTH to BCG antigens by inoculation of either viable BCG or PPD into the footpad (Fig. 3) . All mice inoculated with viable BCG i.p. showed strong, and persistent, DTH responses to both PPD and viable organisms. The footpads of BCG-immune mice, as well as those of untreated controls, were infected with L. major alone or in combination with viable BCG, heat-killed BCG, or PPD. Development of cutaneous lesions was monitored by measuring footpad depths for 12 weeks. Figure 4 demonstrates the dramatic effect of concurrent BCG and L. major infections in BCG-immune animals. Comparison of the lesion size of naive BALB/c mice ( Fig. IA) with that of BCG-immune animals (Fig. 4A) showed a marked modulation of the development of cutaneous disease with prior BCG immunity. The lesion size of most animals pretreated with BCG was 30 to 50% less than that of naive animals. The only treatment protocol that was totally effective in eliminating cutaneous disease in BALB/c mice was the mixture of viable BCG and L. major inoculated into BCG-immune mice. In these mice, the cutaneous lesion completely healed by week 12. Microscopic examination of these healed lesions demonstrated numerous acid-fast bacilli but no amastigotes. Cells present in the tissue were characteristic of an inflammatory infiltrate (polymorphonuclear leukocytes, macrophages, and few lymphocytes). Although decreased in size, lesions did develop in BCG-immune BALB/c mice infected with L. major alone or in combination with heat-killed BCG or soluble PPD. Histologic examination of tissues from these lesions showed numerous amastigotes in macrophages.
The lesions of all BCG-immune P/J mice were substantially smaller (by 50%; Fig. 4B ) than the lesions of naive animals (Fig. 1B) . However, two of the intralesional treatment protocols in BCG-immune P/J mice completely protected the animals from development of a cutaneous lesion: (Fig. 3) . However, Liew et al. (17) 15 days, the mice were injected with 10 pLg of PPD into the infected foot (Fig. 5) . In both BALB/c and P/J mice, intercurrent inoculation of PPD exacerbated leishmanial disease and resulted, particularly in the P/J mice, in substantially larger lesions than the lesions in mice inoculated with L. major alone. Stained impression smears from these infected footpads at 12 weeks showed numerous intracellular amastigotes. It is possible that the increased trauma induced by intermittent inoculation of PPD contributed to exacerbation of the disease (11). Indeed, Titus et al. (31) also observed exacerbation of leishmanial disease with PPD. Thus, BCG qualitatively alters the immune response, and PPD does not.
(ii) Effects on systemic disease. Impression smears of liver tissue at 12 weeks from BCG-immune mice inoculated with L. major alone or in combination with viable BCG, heatkilled BCG, or PPD were examined for the presence of amastigotes (Fig. 6) . Markedly fewer amastigotes were present in the livers of all the BCG-immune animals, and in several of the groups no amastigotes were observed at all (Fig. 6) . The exact pattern of few to no amastigotes was observed in splenic impression smears of these same BCGimmune mice (data not shown). Thus, systemic disease did not develop in mice pretreated i.p. with BCG, regardless of subsequent intralesional treatment. It was not clear from these studies whether systemic infections that occur in naive animals ( Fig. 2) were controlled by BCG in protected animals at the site of metastasis from the cutaneous lesion or within the liver and spleen. To address this point, we examined the popliteal lymph nodes draining the cutaneous lesions of BALB/c mice pretreated with medium or BCG and infected with L. major (Fig. 7) . In all cases, the number of amastigotes in lymph nodes of BCG-treated mice was substantially less than that of untreated mice.
Adjuvant effects of BCG-induced protection in development of immunity to L. major. Six weeks after the initial infection, we inoculated nonspecifically protected BALB/c and P/J mice in the contralateral footpad with L. major alone (no further treatment with BCG). All nonspecifically protected animals rechallenged with L. major alone were completely protected from development of cutaneous and systemic disease (Fig. 8) . Inoculated footpads, draining lymph nodes, livers, and spleens demonstrated no parasites 12 weeks after the rechallenge with inoculum of L. major. In contrast, deaths were observed in the unprotected groups. Five of five BALB/c mice and two of five P/J mice died, and tissues from the surviving mice had numerous infected macrophages at all these anatomical sites. It is interesting to note that footpad swelling, usually a hallmark of cutaneous disease, was completely absent in the rechallenged foot of unprotected P/J mice, despite the presence of numerous parasites in tissues and the fact that two of five animals had died of systemic infection (Fig. 8B) . Primary infection in naive BALB3/c mice was much more complicated. Six weeks after initial infection in BALB/c mice, metastasis of amastigotes occurred in the contralateral foot that resulted in an initial footpad measurement greater than base line at the time of rechallenge. It was impossible to determine the fate of the second parasite inoculum in these mice, since metastatic lesions had already developed. In any case, lesions persisted and grew larger with time in BALB/c mice that had not been pretreated with BCG. admixing L. major and viable BCG in the infectious inoculum, we were able to rescue both mouse strains from lethal systemic infections. This treatment also initiated resolution of cutaneous disease in P/J mice, but BALB/c mice did not fare as well under this treatment protocol.
To protect BALB/c mice from cutaneous disease, we had to establish immunity to BCG before L. major infection and then focus a second immune response at the site of amastigote inoculation. Under these circumstances, we were able not only to protect the mice from lethal systemic disease, but also to prevent chronic cutaneous infections in both BALB/c and P/J mice. The most dramatic effect was observed in P/J mice. These mice cleared the amastigote inoculum completely and never had any evidence of a lesion.
Thus, development of an immune response in the local environment of the leishmanial inoculum was sufficient to prevent the establishment of a focus of infection, and mice that normally die from L. major infections behaved like animals naturally resistant to the parasite. The relative susceptibilities of the two mouse strains were reflected in the different treatment protocols required for protection. P/J mice did not have to be immune to BCG before leishmania inoculation for protection from cutaneous disease to occur. The BALB/c mice, a more susceptible strain, required a rigorous treatment protocol to induce protection. Indeed, other attempts to completely protect BALB/c mice from leishmania infection by systemic treatment with BCG have failed (32) . Our results suggest that intravenous BCG inoculation was not protective in BALB/c mice because the immune response generated by BCG must be focused at the cutaneous lesion site. The success of Bloom (unpublished) in human leishmaniasis may also be attributable to the intralesional (focused) BCG treatment.
One effector function manifest during BCG infection is LK-induced macrophage activation for killing mechanisms. Such activated macrophages are nonspecific in their action; they kill intracellular leishmania just as well as BCG (24) . How this mechanism plays a protective role in either BALB/c or P/J mice is difficult to envisage, since both strains have defective macrophage responses to LK in vitro and in vitro-defined LK defects (18, 19 Not only is intralesional BCG treatment of BCG-immune mice protective against cutaneous and systemic disease, but these mice are also resistant to infection with L. major even when rechallenged without BCG (Fig. 8) (5, 6) . Collectively, these results suggest that BCG has potential as an adjuvant for leishmanial vaccines, which thus far have not been suitable immunogens (10, 14) .
